Country: Կանադա
language: անգլերեն
source: Health Canada
IBUPROFEN
MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC
M01AE01
IBUPROFEN
200MG
TABLET
IBUPROFEN 200MG
ORAL
24/50
OTC
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0108883004; AHFS:
CANCELLED POST MARKET
2016-01-22
PRODUCT MONOGRAPH MOTRIN ® 200 mg Ibuprofen Tablets USP, 200 mg MOTRIN ® Caplet Ibuprofen Tablets USP, 200 mg MOTRIN ® Gelcaps Ibuprofen Tablets USP, 200 mg MOTRIN ® 300 mg Ibuprofen Tablets USP, 300 mg MOTRIN ® 400 mg Ibuprofen Tablets USP, 400 mg Non-Steroidal Anti-inflammatory Drug Analgesic, Antipyretic Agent McNeil Consumer Healthcare Division of Johnson & Johnson Inc. 88 McNabb Street Markham, Canada L3R 5L2 Date of Preparation: May 10, 2002 Date of Revision: February 26, 2015 Control # 181377 _ _ _Page 2 of 41_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ..................................................................................................11 DRUG INTERACTIONS ..................................................................................................15 DOSAGE AND ADMINISTRATION ..............................................................................17 OVERDOSAGE ................................................................................................................18 ACTION AND CLINICAL PHARMACOLOGY ............................................................19 STORAGE AND STABILITY ..........................................................................................21 SPECIAL HANDLING INSTRUCTIONS .......................................................................21 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................21 PART II: SCIENTIFIC INFORMATION ......................................................... read_full_document